<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="195">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05158608</url>
  </required_header>
  <id_info>
    <org_study_id>CY25</org_study_id>
    <nct_id>NCT05158608</nct_id>
  </id_info>
  <brief_title>Comparsion of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis</brief_title>
  <acronym>CY25</acronym>
  <official_title>A Randomized, Open-label, Single-center Study Comparing Cyclophosphamide at a Dose of 25 mg/kg/Day and Cyclophosphamide at a Dose of 50 mg/kg/Day in Graft Versus Host Disease Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Center for Hematology, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Research Center for Hematology, Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two arm open label phase III clinical trial. Adult patients with hematological&#xD;
      malignancies undergoing allogeneic HSCT from any donor are eligible for the study if they&#xD;
      meet the standard criteria defined in the investigator's institutional standard operation&#xD;
      procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria.&#xD;
      Patients will receive reduced-intensity conditioning regimen of fludarabine, busulfan&#xD;
      (treosulfan). Patients will receive PTCy at different dose (25 mg/kg/day vs 50 mg/kg/day on&#xD;
      day +3,+4 in combination with calcineurin inhibitors and mofetil mycophenolate) as GvHD&#xD;
      prophylaxis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute graft-versus-host disease, grades II-IV</measure>
    <time_frame>180 days</time_frame>
    <description>MAGIC criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of chronic GVHD, moderate and severe (NIH criteria)</measure>
    <time_frame>365 days</time_frame>
    <description>NIH criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival analysis</measure>
    <time_frame>365 days</time_frame>
    <description>Kaplan-Meier survival analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival analysis</measure>
    <time_frame>365 days</time_frame>
    <description>Kaplan-Meier survival analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality analysis</measure>
    <time_frame>365 days</time_frame>
    <description>Kaplan-Meier survival analysis, competiting risk analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft failure and poor graft function</measure>
    <time_frame>365 days</time_frame>
    <description>Kaplan-Meier survival analysis, competiting risk analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of 30-Day Readmission</measure>
    <time_frame>365 days</time_frame>
    <description>Kaplan-Meier survival analysis, competiting risk analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <condition>Hematologic Malignancy</condition>
  <condition>Cyclophosphamide Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Cyclophosphamide on day +3,+4 at dose 50 mg/kg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Post-transplantation Cyclophosphamide will be aplly for GVHD prophylaxis on day +3,+4 at dose 50 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide on day +3,+4 at dose 25 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post-transplantation Cyclophosphamide will be aplly for GVHD prophylaxis on day +3,+4 at dose 25 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Post-transplantation Cyclophosphamide at dose 25 mg/kg/day</intervention_name>
    <description>Post-transplantation Cyclophosphamide will be aplly for GVHD prophylaxis on day +3,+4 at dose 25 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.</description>
    <arm_group_label>Cyclophosphamide on day +3,+4 at dose 25 mg/kg/day</arm_group_label>
    <other_name>Endoxan</other_name>
    <other_name>Cyphos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Post-transplantation Cyclophosphamide at dose 50 mg/kg/day</intervention_name>
    <description>Post-transplantation Cyclophosphamide will be aplly for GVHD prophylaxis on day +3,+4 at dose 50 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.</description>
    <arm_group_label>Cyclophosphamide on day +3,+4 at dose 50 mg/kg/day</arm_group_label>
    <other_name>Endoxan</other_name>
    <other_name>Cyphos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have an indication for allogeneic hematopoietic stem cell transplantation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled bacterial or fungal infection at the time of enrollment&#xD;
&#xD;
          -  Requirement for vasopressor support at the time of enrollment&#xD;
&#xD;
          -  Karnofsky index &lt;30%&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Somatic or psychiatric disorder making the patient unable to sign informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Parovichnikova, MD, D.Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Research Center for Hematology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikhail Drokov, MD, Ph.D</last_name>
    <phone>+74956149042</phone>
    <email>mdrokov@gmail.com</email>
  </overall_contact>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 12, 2021</study_first_submitted>
  <study_first_submitted_qc>December 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 12, 2021</last_update_submitted>
  <last_update_submitted_qc>December 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Research Center for Hematology, Russia</investigator_affiliation>
    <investigator_full_name>Mikhail Drokov</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Allogeneic transplantation</keyword>
  <keyword>Graft-versus-host-disease prophylaxis</keyword>
  <keyword>Post-transplant cyclophosphomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

